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CIN2 has a high rate of spontaneous regression in young women and may be managed 
conservatively in appropriately selected patients. This study aimed to investigate health 
outcomes in women aged 18–24 years with biopsy-confirmed CIN2. 
 
Methods: 
A retrospective cohort study of Western Australian women aged 18 to 24 years diagnosed 
with CIN2 on cervical biopsy from 1st January 2001 to 31st December 2010. Women who 
had not received treatment at ≥4 months following CIN2 diagnosis were classified as 
managed ‘conservatively’. Subsequent cervical cytology and/or biopsy test results were used 
to report lesion regression (absence of dysplasia or an epithelial lesion of lower grade than 
CIN2) and disease persistence (CIN2, CIN3 or ACIS). 
 
Results: 
Follow up data were available for 2,417 women of whom 924 (38.2%) were 'conservatively' 
managed. One hundred fifty two (16.4%) conservatively managed women had a lesion more 
severe than CIN2 detected within 24 months of initial diagnosis, of which 144 were CIN3 
and 8 were ACIS. There was no statistically significant association between rates of 
regression and patient age, Socio-Economic Indexes for Areas or Accessibility/Remoteness 
Index of Australia indices. The two-year regression rate for CIN2 was estimated to be 59.5% 
(95% CI 0.5–0.6) in this cohort of women. 
 
Conclusion: 
In conservatively managed young women with CIN2 there was a high rate of spontaneous 
disease regression. Thus, excisional or ablative treatments may be avoided in selected 
patients who receive appropriate counselling and who are able to comply with more intensive 
and prolonged follow-up requirements. 
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Key messages 
Conservatively managed young women with CIN2 had a 59.5% spontaneous regression rate. 
Conservative management is an option for selected patients who receive appropriate 























High-grade cervical intraepithelial neoplasia (CIN) is a precursor to cervical 
squamous cell carcinoma(1-3). The peak incidence of high-grade CIN is in women under age 
25 years but cervical squamous cell carcinoma is rare in this age group(4-7). There are data to 
show that a significant proportion of cases of CIN2 in adolescent and young women (under 
age 21 years) will spontaneously regress(7-9) and because the risk of progression to 
malignancy appears to be low in this age group, excisional or ablative treatment may not be 
indicated.  Young women diagnosed with CIN2 who are likely to comply with follow up may 
be offered conservative management including observation with colposcopy and cytological 
evaluation every 4 to 6 months to permit spontaneous regression of CIN2 and to avoid 
potentially unnecessary and costly treatment(7-12). Excisional treatments such as the loop 
excisional procedure (LEEP) are associated with physical, psychological(13-15) and obstetric 
morbidity(16-18) and may have a negative impact on sexual function(14,19,20). 
Guidelines suggest that conservative management for adolescents with CIN2 may be 
considered in appropriately selected cases, but few studies have addressed this issue in 
women aged 20 to 25 years(7,10). Given the potential for treatment-related complications 
many practitioners have offered women in this age group who are diagnosed with CIN2 the 
option of conservative management. The aim of our study was to investigate the rate of 
spontaneous regression of CIN2 in Western Australian women aged 18 to 24 years to 
determine whether conservative management for appropriately selected patients in this age 
group might be a reasonable alternative to immediate treatment. 
 
Material and methods 
This study was a retrospective cohort study. Women aged 18 to 24 years, were 
followed-up from the time of their first CIN2 diagnosis (cervical biopsy test result) until their 
last cytology/histology record. Ethical approval for this study was granted from the Human 
Research Ethics Committees of Curtin University (ethics research project number: HR 
86/2012 and the Western Australian Department of Health Human Research Ethics 
Committee (ethics research project number: 2012/49).  
The Western Australian Data Linkage System provided a de-identified extraction of 
linked data for the period 1st January 2001 to 31st December 2010 from the Cervical 
Screening Register of WA and the Hospital Morbidity Data System (HMDS). The Western 
Australian Data Linkage System is an internationally renowned, population-based, validated 
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and ongoing data linkage system that creates links among a number of state health 
administrative data sets(21-23).  
The National Cervical Screening Program encourages eligible women (women that 
have not had a hysterectomy and have commenced sexual activity) aged 18 to 69 years to 
have a cervical smear every two years. As part of the National Cervical Screening Program, 
the WA Cervical Cancer Prevention Program maintains and operates the Cervical Screening 
Registry of Western Australia (WA). The Cervical Screening Registry of WA is a voluntary 
“opt-off” confidential register which compiles all cervical test results (cervical smear, 
cervical biopsy and Human Papillomavirus (HPV) tests) that cytopathology laboratories are 
legislatively required to report.  A de-identified dataset was extracted from the CSR of WA 
that contained cervical screening histories for all women aged less than 25 years and who 
resided within WA at the time of their CIN2 diagnosis. Cervical Screening Registry follow-
up data was available until May 2013. 
Women were allocated measures of socioeconomic status using the Socio-Economic 
for Indexes for Areas for Australia obtained through the Australian Bureau of Statistics(24). 
Additionally, women’s postcodes were assigned to one of four Accessibility/Remoteness 
Index of Australia categories(25). Due to small numbers remote and very remote postcodes 
were collapsed into one category for the purposes of this study.  
The Hospital Morbidity Data System records discharge summaries from all Western 
Australian hospitals (private and public and day surgery clinics). For women that did not 
have a biopsy treatment record, the International Classification of Disease code N87.1 for 
moderate cervical dysplasia and associated procedural codes were used to identify women 
that had ablative and excisional techniques performed. Procedural codes included excision 
(cone biopsy by cold knife or laser) and ablation (radical diathermy of cervix, large loop 
excision transformation zone, laser ablation of cervix and other ablative procedures of the 
cervix).  
Cervical cytology test results were classified according to the Australian Modified 
Bethesda System 2004. This classification system is comparable internationally and reflects 
the increased understanding of HPV biology and the development of cervical cancer. In the 
present study we refer to findings from cervical cytology as HSIL or LSIL, whereas 
histological findings are referred to as CIN2 and CIN3. 
Only women aged 18 to 24 years with a histological confirmation of CIN2 were 
included in this study. Women were excluded if they i) had a past history of a histologically 
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confirmed high-grade intraepithelial lesion that was more severe than a CIN2 or (ii) 12 
months of follow-up data (cervical cytology or histology) was unavailable.  
 The Australian Guidelines recommend that women with a cervical smear test result of 
HSIL should be referred to a gynaecologist for colposcopic assessment and targeted biopsy4. 
Ideally women with cervical cytology showing HSIL, or possible HSIL should be assessed 
within two months of diagnosis. Assessment includes colposcopy +/- cervical biopsy. As 
such, women were allocated into a group dependent on when CIN2 treatment (excisional or 
ablative) was performed. To allow for women’s attendance for gynaecological assessment 
and treatment, timeframes were slightly extended to the following: 
1. If the woman was treated for CIN2 within 4 months they were allocated to the 
“immediate treatment” group(4). 
2. If treatment for CIN2 was performed > 4 months women were allocated to the 
“conservative management” group(4,7). 
Outcome measures were disease regression (i.e. negative or low-grade lesions 
including a low-grade squamous intraepithelial lesion (LSIL) on cytology and/or mild 
dysplasia (CIN1) or atypia on a subsequent biopsy), disease persistence including HSIL 
(CIN2, CIN3 or adenocarcinoma-in-situ) and disease progression (cervical cancer). Disease 
regression, persistence or progression was determined from histology test results where 
possible.  
In the absence of histology, cytological findings were used and a hierarchical system 
was adopted to report the most severe diagnosis for the patient. In the event that a patient had 
evidence of regression but at a later follow-up visit cytology or histology confirmed 
persistence or disease progression, the latter diagnosis was reported.  
 
Statistical analysis 
Equality of demographic and clinical characteristics of women on different treatment 
pathways were tested using χ2 tests. Time-to-event analyses were performed to investigate 
factors associated with the rate of regression for women that remained untreated (n=924) for 
CIN2 by 24 months. The follow-up interval was recorded as the time from the CIN2 
diagnosis to disease regression (the event) defined as negative cytology and/or biopsy, LSIL 
or a low-grade glandular abnormality. Participant follow-up was censored at treatment of 
CIN2 disease, progression or at the time of the last available cervical cytology and/or biopsy 
result. If women underwent treatment but had a negative treatment specimen on 
histopathology they were recorded as having had disease regression. Covariates included in 
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the time-to-event analysis were age, socio-economic status and an index of accessibility to 
services. 
Statistical significance was determined as a p-value < 0.05. Stata Version13.0 (Stata 
Corporation, College Station, USA) was used for data manipulation and statistical analysis. 
 
Results 
During the ten-year study period, 2,692 women were aged 18 to 24 years at the time 
of their initial CIN2 diagnosis. Two hundred seventy five women were excluded from the 
study because 12 months of follow-up data (cytology or histology test results) were 
unavailable (n=275). For the remaining 2,417 women, demographic information and 
comparative statistics are reported in Table 1. Conservative   management was more likely 
the younger the age of the woman and in those living in urban areas.  Management approach 
did not vary by socioeconomic status. Thirty eight percent of women had a HSIL (CIN2/3) 
detected on their referral cytology test result within 24 months prior to their CIN2 diagnosis. 
There were 1,493 (61.8%) women who underwent treatment within 4 months of 
diagnosis (immediate treatment group). The mean time from initial diagnosis to treatment 
was 1.5 months in this group. Of the 1,493 women immediately treated, 58 (3.9%) women 
underwent laser ablation of the cervix and no histological specimen was available. Of these 
58 women, 56 had negative follow-up cytology and/or histology findings and two women 
were confirmed to have disease persistence. The remaining 1,435 women were treated by 
either LEEP or cold knife cone biopsy. The majority of women immediately treated had 
CIN2 (62.5%) in their surgical specimen findings (Table 2) and a smaller proportion of 
women either had either negative histopathology or a low-grade cervical abnormality 
(17.3%).  
There were 924 (38.2%) women managed ‘conservatively’. During the 24 month 
follow-up period 25 women subsequently underwent laser ablation and their follow-up 
cytology test results were negative (n=17), LSIL (n=5), possible HSIL (n=<5) and persistent 
HSIL (n=<5). Four hundred thirty seven women who were initially managed conservatively 
subsequently underwent treatment within the 24-month follow-up period by either LEEP (n= 
402) or cervical cold knife cone biopsy (n=35). Their histopathology findings are reported in 
Table 2. Most were CIN2 (22.9%) although a proportion of women (15.6%) had CIN3 
confirmed in their treatment specimen. One hundred fifty two (16.4%) women that had a 
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lesion more severe than CIN2 detected within 24 months of their initial CIN2 diagnosis, of 
which 144 were CIN3 and 8 were ACIS.   
There were 462 women with a histological diagnosis of CIN2 (on cervical punch 
biopsy) who did not undergo treatment during the follow up period. The majority (n=404) of 
these women had repeat cervical cytology within 6 months of initial diagnosis. A small 
proportion (3.7%) subsequently had cervical cytology reported as CIN3 during the study 
follow-up period but are yet to have histological confirmation (outside the study period). In 
445 women follow-up cervical cytology and histology indicated disease regression. The 
median follow-up time for women without a treatment record was 1.8 years. 
Multivariate time to event analysis was performed for those women (n=924) 
conservatively managed to obtain the disease regression hazard rate ratio.  Women were 
censored after treatment and/or when disease progression was confirmed. There was no 
statistically significant association identified between the rate of regression and patient age 
(potentially due to age intervals being very narrow, HR 1.2, 95% CI 1.0 – 1.5), Socio-
Economic for Indexes for Areas for Australia (HR 1.1, 95% CI 1.0 - 1.2) or 
Accessibility/Remoteness Index of Australia indices (HR 1.0, 95% CI 0.8 - 1.1).   
A Kaplan Meir graph (Figure 1) was constructed (censoring women at the time of 
treatment and/or if disease progression was identified) which highlights that the majority of 
women within the “conservative management” group regressed within 12 months following 
their initial CIN2 diagnosis. The two-year CIN2 regression rate was estimated to be 59.5% 






The aim of our study was to investigate disease outcomes of conservatively managed 
women aged 18 to 24 years with biopsy confirmed CIN2. Outcome variables measured 
included rates of CIN2 regression, persistence or progression to higher grade dysplasia or 
invasive cervical cancer or other associated gynaecological disease. Linked administrative 
health data sets were used to ascertain these outcomes in a large cohort of Western Australian 
women with biopsy confirmed CIN2. From Kaplan Meir analysis it was estimated that 59.5% 
of conservatively managed women with CIN2 regressed by 24 months post diagnosis. There 
were no cases of invasive cervical cancer amongst the conservatively managed cohort. 
Furthermore, 331 (13.7%) patients who received immediate or conservative treatment were 
found to have either normal or low-grade histology in the excisional specimen. 
The management of young women (<25 years) with screen-detected cervical 
abnormalities is contentious as there is no clear evidence to suggest that screening patients 
under this age prevents cervical cancer(26-28). Thus, previous management strategies are no 
longer universally accepted for young women with biopsy confirmed CIN2(7,9,11). As such, 
specialist obstetrician/gynaecologists are encouraged to consider offering conservative 
management to appropriately selected patients, in order to minimise potential treatment 
related physical, psychological and obstetric morbidity(7).  
To date there is evidence demonstrating CIN2 regression in up to 65% of adolescents 
and young women (<21 years) over an 18-month period and hence conservative management 
in this population may be warranted(8,9,12). However, only a small number of studies have 
investigated the rate of CIN2 regression in women up to 25 years of age, most of which are 
limited due to their small sample size(7).  To our knowledge this is the largest population-
based study to have analysed outcomes by patient age and socio-economic status in women 
aged 18 to 24 years with biopsy confirmed CIN2. This study contributes to, and reinforces 
the health outcomes highlighted in previous research(7).  
In any study of natural history outcomes in untreated CIN2 an important consideration 
is misclassification of histopathological diagnosis. The reporting of cervical specimens 
(cytology and biopsy specimens) possesses a degree of subjectivity and CIN2 may be over-
diagnosed in some cases. In Australia, laboratories that report cervical abnormalities are 
required to comply with mandatory annual Performance Measures(29) and are subject to 
independent verification of data submitted by the laboratory to the Royal College of 
Pathologists Australasia Cytopathology Quality Assurance Program. These measures have 
enhanced external quality assurance procedures in Australia(29).  
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Limitations of our study include its retrospective design and the error inherent in all 
databases. For example, excisional procedures may have been performed on an outpatient 
basis and not captured in hospital records. However, the mandatory reporting of the 
histological findings of cervical specimens to the Registry ensures data completeness is 
obtained. The quality assurance processes employed ensure the level of error within the 
register is acceptable. A further limitation of our study is the lack of information regarding 
colposcopy findings and therefore no information on other factors, which may have 
influenced whether women were treated immediately or not. This could introduce bias in the 
results. The reason women had treatment performed was not clearly identified and 
consequently treatment intervals were varied. Additionally, disease regression could not 
always be confirmed histologically.  
Furthermore, our inclusion criteria to this study required biopsy confirmation of a 
CIN2 lesion. As such, the lesion may not have ‘truly’ spontaneously cleared as the biopsy 
may have accelerated the clearance of the disease (i.e. specifically if it was a very small 
lesion). It is important to note that CIN2 is the least reproducible of all cervical diagnoses, 
and it is possible that the ‘regression’ of CIN2 is dependent on the individual pathologist 
reporting the lesion(30-33). The potential inclusion of ‘equivocal’ CIN2 lesions could also be 
expected to increase the overall regression rate and consequently, regression may have been 
over-reported(30,31). These limitations emphasize the need for further prospective studies 
that report treatment determinants and also report reproducible biomarkers (i.e. p16 staining 
of CIN2 specimens). 
 In recommending conservative management following the diagnosis of CIN2 patient 
safety is paramount. In our study amongst those patients who were treated conservatively, 
none progressed to invasive cervical cancer, although eight cases of adenocarcinoma in situ 
(ACIS) were identified (0.9%). Amongst those women who received immediate treatment, 
there were cases of ACIS (n = 11), squamous cell carcinoma (n = < 5), and adenocarcinoma 
(n = < 5) that had not been identified initially. These cases highlight the need for cautious 
implementation of a conservative management protocol in young women diagnosed with 
CIN2, and the need for careful selection of patients, regular follow-up evaluation, 
maintenance of clinical standards and appropriate follow-up systems. 
Potential sequelae of conization and LEEP include not only the physical and 
psychological, but also adverse obstetric outcomes such as second trimester miscarriage and 
early pre-term delivery(34,35,36,37). Epidemiological data suggest that these risks correlate 
with depth of excision and are more frequent following conization(34,37). Based on the 
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59.5% regression rate reported in this study conservative treatment of CIN2 may be an 
appropriate option, in the form of regular surveillance, for patients less than 25 years of age. 
These women should remain under specialist care which routinely provides colposcopy, 
cytological testing and quality assurance throughout the patient’s clinical management, for at 
least 24 months prior to invasive treatment. 
 
Acknowledgements 
We gratefully acknowledge the Data Linkage Branch and Data Custodians of the Cervical 
Screening Registry of Western Australia and at the Hospital Morbidity Data System (Western 





















1. Montz FJ. Management of high-grade cervical intraepithelial neoplasia and low-grade 
squamous intraepithelial lesion and potential complications. Clin Obstet Gynecol. 2000;43: 
394-409.  
2. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T et al. Five-year risk 
of CIN 3+ to guide the management of women aged 21 to 24 years. J Low Genit Tract Dis. 
2013;17:S64-8.  
3. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T et al. Five-year 
risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative 
high-grade Pap results. J Low Genit Tract Dis. 2013;17:S50-5.  
4. National Health and Medical Research Council [NHMRC]. Screening to prevent cervical 
cancer: Guidelines for the management of women with screen detected abnormalities. 
Canberra: NHRMC, 2005. 
5. Australian Institute of Health and Welfare [AIHW]. Cervical screening in Australia 2011–
2012. 2014. Canberra: AIHW. 
6. Australian Institute of Health and Welfare [AIHW]. Gynaecological cancers in Australia: 
an overview. Canberra: AIHW.   
7. Mcallum B, Sykes PH, Sadler L, Macnab H, Simcock BJ, Mekhail AK. Is the treatment of 
CIN 2 always necessary in women under 25 years old? Am J Obstet Gynecol. 2011;205:e1- 
7.   
8. Moore K, Cofer A, Elliot L, Lanneau G, Walker J, Gold MA. Adolescent cervical 
dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol. 2007;197: 
e1-6.   
9. Moscicki A, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S et al. Risk of and 
risks for regression of cervical intrapethelial neoplasia in adolescents and young women. 
Obstet Gynecol. 2010;116:1373-80.  
10. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of 
cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113:18-25.   
11. Massad SL, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M et al. 2012 
Updated consensus guidelines for the managment of abnormal cervical cancer screening tests 
and cancer precursors. J Low Genit Tract Dis. 2013;17:S1-27.  
12. Moscicki A. Conservative management of adolescents with abnormal cytology and 
histology. J Natl Canc Netw. 2008;6:101-6.  
12 
 
13. Baileff A. Cervical screening: patients' negative attitudes and experiences. Nurs Stand. 
2000;14:35-7.   
14. Mcdonald TW, Neutens JJ, Fischer LM, Jessee D. Impact of cervical intraepithelial 
neoplasia diagnosis and treatment on self-esteem and body image. Gynecol Oncol. 
1989;34:345-49.  
15. Palmer AG, Tucker S, Warren R, Adams M. Understanding women's responses to 
treatment for cervical intra-epithelial neoplasia. Br J Clin Psychol. 1993;32:101-12.  
16. Bruinsma F, Lumley J, Tan J, Quinn M. Precancerous changes in the cervix and risk of 
subsequent preterm birth. BJOG. 2007;114:70-80. 
17. Houlard S, Perrotin F, Fourquet F, Marret H, Lansac J, Body G. Risk factors for cervical 
stenosis after laser cone biopsy. Eur J Obstet Gynecol Reprod Biol. 2002;104:144-47.   
18. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. 
Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical 
lesions: systematic review and meta-analysis. Lancet. 2006;367:489-98.   
19. Inna N, Phianmongkhol Y, Charoenkwan K. Sexual function after loop electrosurgical 
excision procedure for cervical dysplasia. J Sex Med. 2010;7:1291-97.   
20. Serati M, Salvatore S, Cattoni E, Zanirato M, Mauri S, Siesto G et al. The impact of the 
loop electrosurgical excisional procedure for cervical intraepithelial lesions on female sexual 
function. J Sex Med. 2010;7:2267-72.   
21. Brameld KJ, Thomas MA, Holman CD, Bass AJ, Rouse IL. Validation of linked 
administrative data on end-stage renal failure: application of record linkage to a 'clinical base 
population'. Aust N Z J Public Health. 1999;23:464-67.  
22. Holman CD, Bass AJ, Rosman DL, Smith MB, Semmens JB, Glasson EJ et al. A decade 
of data linkage in Western Australia: strategic design, applications and benefits of the WA 
data linkage system. Aust Health Rev. 2008;32:766-77.  
23. Holman CD, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health records 
in Western Australia: development of a health services research linked database. Aust N Z J 
Public Health.1999;23:453-59.  
24. Australian Bureau of Statistics. Census of Population and Housing: Socio-Economic 
Indexes for Areas (SEIFA), Australia– Data only, 2006. (ABS Cat. No. 2033.0.55.001) 
http://www.abs.gov.au/ausstats/abs@.nsf/mf/2039.0/ [Accessed May 2014].   
25. University of Adelaide. ARIA and Accessibility, 2014. 
https://www.adelaide.edu.au/apmrc/research/projects/category/aria.html [Accessed May 
2014].   
13 
 
26. Castanon A, Leung VM, Landy R, Lim AW, Sasieni P. Characteristics and screening 
history of women diagnosed with cervical cancer aged 20-29 years. Br J Cancer. 2013;109: 
35-41.   
27. Landy R, Birke H, Castanon A, Sasieni P. Benefits and harms of cervical screening from 
age 20 years compared with screening from age 25 years. Br J Cancer [Epidemiology]. 
2014;110:1841-46.   
28. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population 
based case-control study of prospectively recorded data. BMJ. 2009;339:b2968.   
29. Shield PW, Finnimore J, Cummings M, Wright GR. Performance measures for Australian 
laboratories reporting cervical cytology: a decade of data 1998–2008. Pathology. 
2010;42:623-28.  
30. Robertson AJ, Anderson JM, Beck JS, Burnett RA, Howatson SR, Lee FD et al. Observer 
variability in histopathological reporting of cervical biopsy specimens. J Clin Pathol. 
1989;42:231–38. 
31. Stoler MH, Schiffman H. Interobserver reproducibility of cervical cytologic and 
histologic interpretations: realistic estimates from the ASCUS-LSIL triage study. JAMA 
2001;285:1500–05. 
32. Gage JC, Hanson VW,  Abbey K, Dippery S, Gardner S, Kubota J et al. Number of 
cervical biopsies and sensitivity of colposcopy. Obstet Gynecol. 2006;108:264–72. 
33. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X et al. 
Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the 
diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol. 
2004;191:430–34. 
34. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al. 
Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of 
cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;18;a1284.  
35. Long S, Leeman L. Treatment options for high-grade squamous intraepithelial lesions. 
Obstet Gynecol Clin North Am. 2013;40:291-316. 
36. Frederiksen ME, Njor S, Lynge E, Rebolj M. Psychological effects of diagnosis and 
treatment of cervical intraepithelial neoplasia: a systematic review. Sex Transm Infect. 
2015;91:248-56. 
37. Berretta R, Salvatore G, Dall’Asta A. Risk of preterm delivery associated with prior 


















Women’s age (years) 
18 – 19 
 
208 13.9 176 19.1  
 
0.003 20 – 21 464 31.1 281 30.4 
22 – 24 821 55.0 467 50.5 
Women’s referral cytology test result (within 24 months of biopsy confirmed CIN2 diagnosis) 












6 0.4 20 2.2 
HSIL  (CIN2/3) 567 38.0 439 47.5 
No referral cytology 
test result present 
894 59.9 400 43.3 
Accessibility/Remoteness Index of Australia 
Major city 995 66.6 690 74.7  
 
0.002 
Inner regional 235 15.7 109 11.8 
Outer regional 128 8.6 60 6.5 
Remote/very remote 117 7.9 58 6.3 
Unknown  
(Post Office Box) 





Socio-Economic Indexes for Areas of Australia 
Least disadvantaged 467 31.3 323 35.0  
 
0.315 
Less disadvantage 243 16.3 155 16.8 
Middle 334 22.4 181 19.6 
More disadvantaged 266 17.8 165 17.8 
Most disadvantaged 165 11.0 93 10.1 
Unknown  
(Post Office Box) 
18 1.2 7 0.7 



















Table 2  Treatment performed and final histologic condition at time of 
treatment by management category (within 12 months of CIN2 














Laser destruction 58 3.9 25 2.7 
Cold knife cone biopsy 138 9.2 35 3.8 
LEEP 1,297 86.9 402 43.5 
No treatment record present 
(within 24 months of CIN2 
diagnosis)* 
0 0 462 50.0 
Treatment outcome 
Negative 82 5.5 24 2.6 
Low-grade intraepithelial 
abnormality 
176 11.8 49 5.3 
CIN2 933 62.5 212 22.9 
CIN3 231 15.5 144 15.6 
Adenocarcinoma-in-situ 11 0.7 8 0.9 
Squamous cell carcinoma <5** - 0 0.0 
Adenocarcinoma <5** _ 0 0.0 
No treatment outcome available 58 3.9 487 52.7 
* No histologic condition was reported because cervical cytology test results were used to 
determine the outcome in the conservative treatment group, or the treatment was ablation and 
no histologic condition was available. 






Figure 1  Kaplan Meir Curve showing the proportion of women who underwent 
conservative treatment (n=924) who remained with CIN2 within 24 
months of initial diagnosis.  Women were censored at time of 
treatment or when disease progression was identified as they could not 
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